Funding profile · Consumer genomics

Genomelink

Nine years old, three accelerators, and no SEC Form D. Four commercial databases report four different totals for the same company, and there is no federal filing to settle the question.

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reading the filings

1. The absence is legal, and it is still an absence.A company that raises under Section 4(a)(2) rather than Regulation D files no Form D at all, so zero filings does not mean zero money. It does mean every dollar figure below rests on private database entries or on the founder’s own account, with no dated federal document behind any of them.
2. The four totals differ by a factor of forty.Tracxn records $225K across three seed rounds. CB Insights records $4.49M across seven. PitchBook records roughly $9M and 18 investors. The co-founder told Berkeley SkyDeck in July 2025 that the company had raised $10M for its Series A. Tracxn covers only three of the ten or eleven events the other two list, which explains its low figure but not the gap between $4.49M and $10M.
3. Only one round carries both a date and a number.PitchBook logs $450,000 on December 15, 2017, and labels it Series A. The founder describes a Series A that began at a SkyDeck alumni demo day, continued through Y Combinator’s Summer 2021 demo day, and reached $10M step by step. Those two uses of Series A sit four years and roughly twenty two times apart.
4. The investor count rises faster than the capital.Seventeen investors at Tracxn, eighteen at PitchBook, twenty two at CB Insights. Against PitchBook’s $9M that averages about $500,000 each; against CB Insights’s $4.49M it averages about $204,000 each. Either figure describes angels, accelerators and small corporate checks rather than a priced institutional round.
5. The cap table fragment points the same way.PitchBook shows two priced series with issue prices of $0.15 and $0.40 and 837,944 and 861,308 shares authorized, holding 6.89 and 7.09 percent. At those prices the two series together cap out near $470,000 if every authorized share was sold. Authorized is not issued, so read it as a ceiling, and a low one.
6. The most recent recorded event is a secondary, not a raise.PitchBook’s latest deal type is a private secondary transaction with no date and no amount. Secondaries move existing shares between holders; they put no new cash into the company.

Commercial signals

What to watch

• A first Form D. It would be the first federally dated fact about this company’s capital.
• An FDA submission or registered trial for T1D Scout, which is marketed as a clinical product and has neither.
• Whether the secondary transaction PitchBook records signals early holders taking liquidity ahead of a priced round.
• Any disclosed subscriber or revenue figure. None is published.

The Genomelink story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Data Driven Bioscience: Shared investor: Brighter Capital. A Durham company that sells hospital laboratories a kit for reading a tumor’s DNA and RNA in a single preparation, on the sequencer the lab already owns
• Epinoma: Shared investor: Asymmetry Ventures. A four-person startup selling EpiAmp, a chemistry that copies DNA while keeping its methylation marks
• Clear Gene: Shared investor: Asymmetry Ventures. An RNA test built to tell a surgeon whether the whole tumor came out
• BluumBio: Shared investor: Asymmetry Ventures. A four-person Berkeley company making microbial products that eat industrial pollution

Sources

1. Public recordEDGAR company and full text searches for Genomelink and Awakens, Inc., zero resultsSEC · Sep 23, 2026
2. Public recordopenFDA 510(k) searches and ClinicalTrials.gov searches, no recordsFDA, NIH · Sep 23, 2026
3. Public recordPMID 36076307 and PMID 39218908, with corporate affiliationsHuman Genomics · 2022 and 2024
4. IndependentGenomelink profile: funding, cap table, patents, investorsPitchBook · accessed Sep 2026
5. IndependentGenomelink funding, valuation and revenueCB Insights · accessed Sep 2026
6. IndependentGENOME LINK funding rounds and list of investorsTracxn · accessed Sep 2026
7. InterviewAgainst the Odds: How One Japanese Startup Got Its Start in the U.S.Berkeley SkyDeck, Sibyl Chen · Jul 17, 2025
8. IndependentGenomelink Review (2026), pricing and Trustpilot data verified May 20, 2026KnowYourDNA, Joel Hirsch
9. CompanyGenomelink company page, batch Summer 2021Y Combinator · Sep 2026
10. CompanyPrivacy Policy and Terms of UseGenomelink · effective Sep 14, 2026
11. PartnerT1D Strong DNA test page and T1D Scout coverageT1D Strong · 2026

Compiled from SEC, FDA, NIH and other public records, commercial private market databases and published reports as of September 23, 2026. No Form D has been filed for this company; amounts shown are as reported by third party databases or by the company, and are labeled accordingly. Healthcare Venture Capital Fund holds no position in Genomelink. This page is not an offer to sell or a recommendation to buy any security.